Dydrogesterone‐primed ovarian stimulation is an effective alternative to gonadotropin‐releasing hormone antagonist protocol for freeze‐all cycles in polycystic ovary syndrome. Issue 8 (4th June 2020) - Gurbuz, Ali Sami
Abstract: Objective: To compare the effects of progestin‐primed ovarian stimulation using dydrogesterone (DYD) and a gonadotropin‐releasing hormone (GnRH) antagonist protocol on cycle characteristics and pregnancy rates in freeze‐all cycles in patients with polycystic ovary syndrome (PCOS). Methods: Medical records of PCOS patients who underwent freeze‐all in vitro fertilization cycles between April 2017 and April 2019 at the Novafertil in vitro fertilization Center were retrospectively evaluated. The primary outcome measure was the incidence of premature luteinizing hormone surge. Secondary outcome measures were the total number of mature oocytes retrieved, fertilization rate, clinical pregnancy rates and ongoing pregnancy rates. Results: A total of 525 patients were included in the study. DYD‐primed ovarian stimulation and a GnRH antagonist protocol were applied in 258 and 267 patients, respectively. The baseline parameters were similar between the two groups. The numbers of mature and fertilized oocytes were similar in the cetrorelix (CET) group and DYD group (11.43 ± 3.48 vs. 11.29 ± 4.34, respectively, P = 0.692; and 8.98 ± 2.93 vs. 8.62 ± 3.67, respectively, P = 0.208). Premature luteinization was rare in both groups, and the difference between the groups was not statistically significant (2.9% vs. 1.5%, respectively, P = 0.268). There was no significant difference in clinical pregnancy rate of the first frozen embryo transfer cycle between the DYG group and the CET group (56% [120/214] vs. 55.6% [113/203], respectively, P = 0.283). There were no significant differences in biochemical pregnancy rates, implantation rates, miscarriage rates or ongoing pregnancy rates between the two groups ( P > 0.05). Conclusion: Dydrogesterone‐primed ovarian stimulation seems to be an effective alternative to the GnRH antagonist protocol for freeze‐all cycles in PCOS patients.